Annual Securities Report — FY2025
What Mochida Pharmaceutical Co.,Ltd. reported for the period from 2025-04-01 to 2026-03-31.
Filed 2026-06-24View the original on EDINET
How much it says
72Detailed
What moved here
40named for the first time
Its own wording
65terms
Which filing this is
36/ 36newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
In the consolidated fiscal year ended 31 March 2026 (1 April 2025 to 31 March 2026), revenue increased to ¥116,951 million year on year, while operating income, ordinary income and net income attributable to owners of the parent also increased. The Company also acquired a 20% stake in And Pharma Co., Ltd. effective 1 October 2025, making it an equity-method affiliate, and disclosed its dividend policy for the following fiscal year and initiatives based on the medium-term management plan.
Komori's summary of this document, not the document's own words.72Detailed
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 36 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
76
Very detailed
61
Detailed
54
Typical
75
Very detailed
100
Very detailed
68
Detailed
77
Very detailed
100
Very detailed
60
Detailed
79
Very detailed
50
Typical
R&D spend122億円Money spent making new things.
Cash left over-92億円Cash from the business, less what went into equipment.
Spent on equipment0百万円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.